American Oriental Bioengineering’s (AOB) third quarter earnings per share came in at 13 cents, well below the Zacks Consensus Estimate of 19 cents and 21 cents in the year ago period. The company derives revenues from two operating segments – Manufacturing and Distribution. During the quarter, Manufacturing accounted for more than 95% of the company’s total revenues.

Total revenues increased 11.7% year over year to $78.8 million. American Oriental records Manufacturing revenues from two sources – Pharmaceutical and Nutraceutical products. Both sources recorded an increase of 6.3% to $66 million and 8.2% to $9.2 million, respectively, compared to the third quarter of 2008. The company generated $3.6 million from its Distribution business during the reported quarter.

Revenues from prescription pharmaceutical products increased 22.7% to $29.8 million during the quarter, primarily driven by increased sales of Jinji capsule, Boke and CCXA products, partially offset by decline in sales of Shuanghuanglian injection

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

PWRM, AMLN

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday November 2nd, 2009, are:

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for

China Medicine Corp. is a developer and leading distributor of prescription and over-the-counter drugs, traditional Chinese medicine products, nutritional and dietary supplements, and medical devices and formulations in China.

The company announced today that through its wholly-owned subsidiary in China, Konzern Pharmaceuticals, it has signed an equity transfer agreement to acquire 100% of equity interests in Sinoform Limited, a British Virgin Islands corporation which is the sole shareholder of Guangzhou LifeTech Pharmaceuticals. LifeTech Pharmaceuticals is a developer, manufacturer and marketer of pharmaceutical products and traditional Chinese medicines in China.

The acquisition is expected to close before the end of the year and China Medicine will acquire Guangzhou LifeTech for 57 million renminbi or about $8.3 million cash and the assumption of about $13.2 million in debt. Upon closing of the acquisition, the company will receive all of LifeTech’s assets, including a portfolio of 39 Western and traditional Chinese medicine products. LifeTech’s top-selling

On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.

GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday October 27, 2009, are:

**************************************************************

GSK, GlaxoSmithKline plc

GSK, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter medicines, and health related consumer products. GSK operates in two segments, Pharmaceutical and Consumer Healthcare.

** The Food and Drug Administration Monday approved Arzerra, a leukemia treatment that will be marketed by GSK for patients who have failed to respond to other therapies.

More about GSK at www.gsk.com

**************************************************************

EVRN, Everock Inc., EVRN.PK

EVRN produces a line of all-natural gourmet vegetable dips and sandwich spreads marketed under the Nature’s Peak brand.

Both

Risk is just that, risk. Investing in opportunity is never easy but can return financial rewards. Understanding the risk is the key. Pick an investment that fits your needs. Finding that investment, and waiting to see if you are correct, is the key.

Rexahn Pharmaceuticals Inc., a clinical biopharmaceutical drug development company, works to develop drug products oriented toward a variety of conditions. The company is currently progressing through Phase IIa for an anti-depressant product.

Although the company has a variety of pharmaceutical products in development, its relationships around the world may be its largest asset. Universities to corporations have developed licensing arraignments with the company that will, in all likelihood, result in solid marketing and profitability as products become approved. These relationships may also result in opportunities as they relate to the company being purchased or leveraged by larger pharmaceutical companies. In the “big pharma” world this is a key trend

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Monday October 12, 2009

DrStockPick.com Stock Report!

**************************************************************

Synopsys, Inc. (Nasdaq: SNPS), a world leader in software and IP for semiconductor design, verification and manufacturing, today introduced its Synphony HLS (High Level Synthesis) solution that integrates M-language and model-based synthesis to deliver up to 10X higher design and verification productivity than traditional RTL flows for communications and multimedia applications. Synphony HLS creates optimized RTL for ASIC and FPGA implementation, architecture exploration and rapid prototyping. In addition, Synphony HLS complements C/C++-based flows by generating C-models for system

It was a Wednesday afternoon when Cubist Pharmaceuticals have publicly announced that they have been named to be in the top spot in the MassEcon Sixth Annual Team Massachusetts Economic Impact Awards in the Greater Boston Region. The Massachusetts Alliance for Economic Development also known as MassEcon is a private, non-profit partnership of business, industry leaders and government who are working hard for the economic growth of Massachusetts. With two other pharmaceutical companies bagging the silver and bronze level, it was the life science companies that sweep the awards in the Greater Boston Region.

Cubist Pharmaceuticals Inc. is a biopharmaceutical company that is into the research and development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

The winning companies were judged on their investment in

Formerly known as Ophthalmic Technologies Inc. Opko Health has recently agreed to acquire Chilean pharmaceutical company named Pharma Genexx for around US$ 16 million in cash. One of the reasons why this Florida-based pharma giant is taking up Chilean pharmaceutical is to enter the emerging markets in the future. The Miami-based Opko Health is a specialty healthcare company that is currently involved in the discovery, development and commercialization of pharmaceutical products, vaccines and diagnostic technologies. However, with this acquisition Opko Health is looking to expand into new areas like oncology and neurological disorders.

Opko Health CEO and Chairman Philip Frost have said that Opko Health believes that this acquisition will be an excellent strategic fit for Opko to expand further into international market. Currently, Pharma Genexx is involved in the representation,